肾肿块活检后并发症:频率、性质、发生时间及相关特征
该回顾性研究纳入576例超声或CT引导下经皮肾肿块活检患者,急性并发症发生率3.6%,亚急性0.7%,无迟发并发症或死亡。出血相关急性并发症均在162分钟内出现偏离临床常规管理,血小板计数较低和完全内生性肾肿块与出血并发症相关。建议活检后监测3小时再出院。
要点
- 肾肿块活检后急性并发症多表现为出血相关,且多在3小时内出现临床管理偏离。
- 完全内生性肾肿块和血小板计数较低者出血并发症风险较高。
- 无并发症患者中仅1.6%出现临床管理偏离,3小时监测窗口可能安全有效。
核心结论
- 肾肿块活检后并发症不常见,急性并发症在3小时内出现,亚急性并发症在24小时后出现。
研究设计与样本
- 回顾性研究,纳入576例患者(平均年龄64.9岁,男345例,女231例),来自三家医院,由22名放射科医生在2008年1月1日至2020年6月1日期间行超声或CT引导下经皮肾肿块活检。
- 通过电子健康记录审查识别活检后并发症,分类为出血相关或非出血相关,以及急性(<24小时)、亚急性(24小时至30天)或迟发(>30天)。
关键影像表现/征象
- 急性并发症发生率为3.6%(21/576),其中76.2%(16/21)为出血相关。
- 亚急性并发症发生率为0.7%(4/576),发生于活检后28小时至18天。
- 无迟发并发症或患者死亡。
- 出血相关急性并发症患者中,从正常临床管理偏离的平均时间为56±47分钟(范围10-162分钟;13/16例≤120分钟)。
- 非出血相关急性并发症(5例)均在活检完成时出现。
诊断标准与关键数值
- 无活检后并发症的551例活检中,1.6%(9/551)出现偏离正常临床管理。
临床应用与阅片要点
- 肾肿块活检后建议监测3小时,若无临床管理偏离且告知患者亚急性并发症低风险,可安全出院。
- 对于血小板计数较低或完全内生性肾肿块患者,应警惕出血相关并发症。
- 非出血相关急性并发症多在活检完成时出现,出血相关并发症多在3小时内出现偏离。
局限性
- 回顾性研究设计。
- 来自三家医院,但未报告多中心外部验证。
- 样本量576例,亚急性并发症仅4例,相关因素分析可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Observation periods after renal mass biopsy (RMB) range from 1 hour to overnight hospitalization. Short observation may improve efficiency by allowing use of the same recovery bed and other resources for RMBs in additional patients. OBJECTIVE. The purpose of this study was to evaluate the frequency, timing, and nature of complications after RMB, as well as to identify characteristics associated with such complications. METHODS. This retrospective study included 576 patients (mean age, 64.9 years; 345 men, 231 women) who underwent percutaneous ultrasound- or CT-guided RMB at one of three hospitals, performed by 22 radiologists, between January 1, 2008, and June 1, 2020. The EHR was reviewed to identify postbiopsy complications, which were classified as bleeding-related or non-bleeding-related and as acute (< 24 hours), subacute (24 hours to 30 days), or delayed (> 30 days). Deviations from normal clinical management (analgesia, unplanned laboratory testing, or additional imaging) were identified. RESULTS. Acute and subacute complications occurred after 3.6% (21/576) and 0.7% (4/576) of RMBs, respectively. No delayed complication or patient death occurred. A total of 76.2% (16/21) of acute complications were bleeding-related. A deviation from normal clinical management occurred after 1.6% (9/551) of RMBs that had no associated postbiopsy complication. Among the 16 patients with bleeding-related acute complications, all experienced a deviation, with mean time to deviation of 56 ± 47 (SD) minutes (range, 10-162 minutes; ≤ 120 minutes in 13/16 patients). The five non-bleeding-related acute complications all presented at the time of RMB completion. The four subacute complications occurred from 28 hours to 18 days after RMB. Patients with, versus those without, a bleeding-related complication had a lower platelet count (mean, 197.7 vs 250.4 × 109/L, p = .01) and greater frequency of entirely endophytic renal masses (47.4% vs 19.6%, p = .01). CONCLUSION. Complications after RMB were uncommon and presented either within 3 hours after biopsy or more than 24 hours after biopsy. CLINICAL IMPACT. A 3-hour monitoring window after RMB before patient discharge (in the absence of deviation from normal clinical management and complemented by informing patients of the low risk of a subacute complication) may provide both safe patient management and appropriate resource utilization.
引用
- Robert, Cossetto, Miao, et al. Complications After Renal Mass Biopsy: Frequency, Nature, Timing, and Associated Characteristics. AJR Am J Roentgenol. 2023. PMID: 37132549. doi:10.2214/AJR.23.29059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。